Alzheimer&rsquo
s disease (AD) is a neurodegenerative disease, which is accompanied by memory loss and cognitive dysfunction. Although a number of trials to treat AD are in progress, there are no drugs available that inhibit the progression of AD. As the aggregation of amyloid-&beta
(A&beta
) peptides in the brain is considered to be the major pathology of AD, inhibition of A&beta
aggregation could be an effective strategy for AD treatment. Jowiseungchungtang (JWS) is a traditional oriental herbal formulation that has been shown to improve cognitive function in patients or animal models with dementia. However, there are no reports examining the effects of JWS on A&beta
aggregation. Thus, we investigated whether JWS could protect against both A&beta
aggregates and A&beta
mediated pathology such as neuroinflammation, neurodegeneration, and impaired adult neurogenesis in 5 five familial Alzheimer&rsquo
s disease mutations (5XFAD) mice, an animal model for AD. In an in vitro thioflavin T assay, JWS showed a remarkable anti-A&beta
aggregation effect. Histochemical analysis indicated that JWS had inhibitory effects on A&beta
aggregation, A&beta
induced pathologies, and improved adult hippocampal neurogenesis in vivo. Taken together, these results suggest the therapeutic possibility of JWS for AD targeting A&beta
mediated neurodegeneration, and impaired adult hippocampal neurogenesis.